917 related articles for article (PubMed ID: 32561292)
1. Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib.
Emori T; Kasahara M; Sugahara S; Hashimoto M; Ito H; Narumiya S; Higashi Y; Fujii Y
Eur J Pharmacol; 2020 Sep; 882():173238. PubMed ID: 32561292
[TBL] [Abstract][Full Text] [Related]
2. Peficitinib Inhibits the Chemotactic Activity of Monocytes via Proinflammatory Cytokine Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes.
Ikari Y; Isozaki T; Tsubokura Y; Kasama T
Cells; 2019 Jun; 8(6):. PubMed ID: 31181818
[No Abstract] [Full Text] [Related]
3. Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib.
Diller M; Hasseli R; Hülser ML; Aykara I; Frommer K; Rehart S; Müller-Ladner U; Neumann E
Front Immunol; 2019; 10():541. PubMed ID: 30984167
[No Abstract] [Full Text] [Related]
4. Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function.
O'Brien A; Hanlon MM; Marzaioli V; Wade SC; Flynn K; Fearon U; Veale DJ
Front Immunol; 2021; 12():672461. PubMed ID: 34248953
[TBL] [Abstract][Full Text] [Related]
5. The JAK inhibitor baricitinib inhibits oncostatin M induction of proinflammatory mediators in ex-vivo synovial derived cells.
Weston S; Macdonald JL; Williams LM; Roussou E; Kang NV; Kiriakidis S; Taylor PC
Clin Exp Rheumatol; 2022 Sep; 40(9):1620-1628. PubMed ID: 34665696
[TBL] [Abstract][Full Text] [Related]
6. In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors.
Kitanaga Y; Imamura E; Nakahara Y; Fukahori H; Fujii Y; Kubo S; Nakayamada S; Tanaka Y
Rheumatology (Oxford); 2020 Aug; 59(8):1957-1968. PubMed ID: 31764973
[TBL] [Abstract][Full Text] [Related]
7. CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes.
Migita K; Komori A; Torigoshi T; Maeda Y; Izumi Y; Jiuchi Y; Miyashita T; Nakamura M; Motokawa S; Ishibashi H
Arthritis Res Ther; 2011 May; 13(3):R72. PubMed ID: 21548952
[TBL] [Abstract][Full Text] [Related]
8. CYT387 Inhibits the Hyperproliferative Potential of Fibroblast-like Synoviocytes via Modulation of IL-6/JAK1/STAT3 Signaling in Rheumatoid Arthritis.
Srivastava S; Samarpita S; Ganesan R; Rasool M
Immunol Invest; 2022 Aug; 51(6):1582-1597. PubMed ID: 34704880
[TBL] [Abstract][Full Text] [Related]
9. Anti-apoptotic effect of interleukin-22 on fibroblast-like synoviocytes in patients with rheumatoid arthritis is mediated via the signal transducer and activator of transcription 3 signaling pathway.
Zhao M; Li Y; Xiao W
Int J Rheum Dis; 2017 Feb; 20(2):214-224. PubMed ID: 27493089
[TBL] [Abstract][Full Text] [Related]
10. Peficitinib inhibits fibroblast-like synoviocyte activation and angiogenic vascular endothelial tube formation via inhibitory effects on PDGF and VEGF signaling in addition to JAK.
Ishikawa G; Kwon C; Fujii Y
J Pharmacol Sci; 2022 Oct; 150(2):74-80. PubMed ID: 36055754
[TBL] [Abstract][Full Text] [Related]
11. The Janus kinase inhibitor (baricitinib) suppresses the rheumatoid arthritis active marker gliostatin/thymidine phosphorylase in human fibroblast-like synoviocytes.
Joyo Y; Kawaguchi Y; Yonezu H; Senda H; Yasuma S; Shiraga H; Nozaki M; Aoyama M; Asai K; Murakami H; Waguri-Nagaya Y
Immunol Res; 2022 Apr; 70(2):208-215. PubMed ID: 35014010
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
13. Matrine induces the apoptosis of fibroblast-like synoviocytes derived from rats with collagen-induced arthritis by suppressing the activation of the JAK/STAT signaling pathway.
Yang Y; Dong Q; Li R
Int J Mol Med; 2017 Feb; 39(2):307-316. PubMed ID: 28035365
[TBL] [Abstract][Full Text] [Related]
14. The Janus kinase inhibitor tofacitinib inhibits TNF-α-induced gliostatin expression in rheumatoid fibroblast-like synoviocytes.
Kawaguchi Y; Waguri-Nagaya Y; Tatematsu N; Oguri Y; Kobayashi M; Nozaki M; Asai K; Aoyama M; Otsuka T
Clin Exp Rheumatol; 2018; 36(4):559-567. PubMed ID: 29352846
[TBL] [Abstract][Full Text] [Related]
15. Cyanidin prevents the hyperproliferative potential of fibroblast-like synoviocytes and disease progression via targeting IL-17A cytokine signalling in rheumatoid arthritis.
Samarpita S; Ganesan R; Rasool M
Toxicol Appl Pharmacol; 2020 Mar; 391():114917. PubMed ID: 32044269
[TBL] [Abstract][Full Text] [Related]
16. Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium.
Migita K; Koga T; Komori A; Torigoshi T; Maeda Y; Izumi Y; Sato J; Jiuchi Y; Miyashita T; Yamasaki S; Kawakami A; Nakamura M; Motokawa S; Ishibashi H
J Rheumatol; 2011 Nov; 38(11):2309-17. PubMed ID: 21844139
[TBL] [Abstract][Full Text] [Related]
17. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib enhances IGF1 via inhibiting STAT6 transcriptionally activated-miR-425-5p to ameliorate inflammation in RA-FLS.
Liu Y; Peng J; Xiong X; Cheng L; Cheng X
Mol Cell Biochem; 2022 Oct; 477(10):2335-2344. PubMed ID: 35536531
[TBL] [Abstract][Full Text] [Related]
19. Targeted inhibition of Janus kinases abates interfon gamma-induced invasive behaviour of fibroblast-like synoviocytes.
Karonitsch T; Beckmann D; Dalwigk K; Niederreiter B; Studenic P; Byrne RA; Holinka J; Sevelda F; Korb-Pap A; Steiner G; Smolen JS; Pap T; Kiener HP
Rheumatology (Oxford); 2018 Mar; 57(3):572-577. PubMed ID: 29228301
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
Front Immunol; 2021; 12():738481. PubMed ID: 34630419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
